Innate Pharma S.A. ADS (IPHA)
IPHA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1598599/000159859926000005/0001598599-26-000005-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | IPHA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | France |
| IPO year | 2019 |
| SEC CIK | 0001598599 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | France |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $10.0M |
| Net income | -$54.4M |
| Operating income | -$59.7M |
| Net margin | -546.1% |
| Operating margin | -599.8% |
| Revenue growth | -55.2% |
| Cash | $31.0M |
| Total assets | $69.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 15.8× |
Reported in EUR; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions and events raise material uncertainty (or raise substantial doubt as contemplated by PCAOB standards) on the Company's ability to continue as a going concern." | 20-F 2026-04-01 |
| Cash and burn | 28.1M EUR cash; operating cash flow -13.2M EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | 93,719,323 (2025-12-31); 83,830,336 a year earlier; 79,542,627 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Associés, Le Bouscat, France | PCAOB Form AP 2026-05-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 9.0M EUR | -49.2M EUR | -52.8M EUR | 28.1M EUR | No debt tags | 9.0M EUR | 20-F 2026-04-01 |
| FY 2024 2024-12-31 | 20.1M EUR | -49.5M EUR | -6.9M EUR | 66.4M EUR | No debt tags | 20.1M EUR | 20-F 2026-04-01 |
| FY 2023 2023-12-31 | 61.6M EUR | -7.6M EUR | -32.6M EUR | 70.6M EUR | No debt tags | 61.6M EUR | 20-F 2026-04-01 |
| FY 2022 2022-12-31 | 57.7M EUR | -58.1M EUR | -19.2M EUR | 84.2M EUR | No debt tags | 57.7M EUR | 20-F 2025-04-30 |
| FY 2021 2021-12-31 | 24.7M EUR | -52.8M EUR | -58.5M EUR | 103.8M EUR | No debt tags | 24.7M EUR | 20-F 2024-04-04 |
| FY 2020 2020-12-31 | 69.8M EUR | -64.0M EUR | -51.8M EUR | 136.8M EUR | No debt tags | 69.8M EUR | 20-F 2023-04-06 |
| FY 2019 2019-12-31 | 85.4M EUR | -20.8M EUR | 34.9M EUR | 202.9M EUR | No debt tags | 85.4M EUR | 20-F 2022-04-04 |
| FY 2018 2018-12-31 | 94.0M EUR | 3.0M EUR | -32.5M EUR | 152.3M EUR | No debt tags | 94.0M EUR | 20-F 2021-04-27 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-02-06 |
| Latest annual report | 20-F | 2026-04-01 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 340 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.2% |
| 1 month | -6.1% |
| 3 months | -45.6% |
| Year to date | -21.1% |
| 1 year | -24.2% |
| From 52-week high | -45.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IVVD | Invivyd Inc. | $0.5377 | -7.63% | $158.5M |
| STRO | Sutro Biopharma Inc. | $9.32 | -5.09% | $154.7M |
| HUMA | Humacyte Inc. | $0.5403 | -3.24% | $150.1M |
| TARA | Protara Therapeutics Inc. | $2.38 | -5.93% | $146.5M |
| FATE | Fate Therapeutics Inc. | $1.14 | -10.94% | $138.6M |
| PALI | Palisade Bio Inc. | $1.03 | -8.04% | $184.7M |
| CGEN | Compugen Ltd. | $2.04 | -2.86% | $193.0M |
| ENGN | enGene Therapeutics Inc. | $1.89 | -21.58% | $126.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier